TELO FY 2024 Earnings — Telomir Pharmaceuticals, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

TELOTelomir Pharmaceuticals, Inc. Common Stock

$46M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$12M

Net Income

-$17M

EPS (Diluted)

$-0.56

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1M

Total Liabilities

$680,968

Stockholders' Equity

$643,037

Cash & Equivalents

$1M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$12M	-$4M	-210.6%
Net Income	-$17M	-$13M	-26.5%